

# **AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1**

Sep 19, 2019

---

**Source URL:** <https://qa1.novartis.us/us-en/news/media-releases/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular-atrophy-sma-type-1-0>

## **List of links present in page**

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/avexis-presents-new-data-epns-continuing-show-significant-therapeutic-benefit-zolgensma-prolonging-event-free-survival-now-5-years-age-patients-spinal-muscular-atrophy-sma-type-1-0>